Literature DB >> 11044914

Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction of short- and long-term repopulating cells.

A W Wognum1, T P Visser, K Peters, M F Bierhuizen, G Wagemaker.   

Abstract

The effects of cytokine stimulation during retroviral transduction on in vivo reconstitution of mouse hematopoietic stem cells was tested in a murine competitive repopulation assay with alpha-thalassemia as a marker to distinguish donor and recipient red blood cells (RBCs) and the enhanced green fluorescent protein (EGFP) as a marker for gene transfer. After transplantation, EGFP was detected in up to 90% of circulating RBCs, platelets, and leukocytes, and in primitive progenitors in bone marrow (BM), spleen, and thymus of individual transplanted mice for observation periods of more than 6 months. Large quantitative differences in reconstitution were observed after transplantation with graded numbers (1000-30, 000) of EGFP(+) cells preconditioned with various combinations of Kit ligand (KL), FLT-3 ligand (FL), thrombopoietin (TPO), interleukin 3 (IL-3), and IL-11. Relative to nonmanipulated BM cells, repopulation of EGFP(+) cells was maintained by KL/FL/TPO stimulation, but approximately 30-fold reduced after KL/FL/TPO/IL-3, or KL/FL/IL-3/IL-11. These differences were not caused by changes in the ability of immature hematopoietic cells to home to the BM, which was only moderately reduced. In conclusion, these quantitative transplantation studies of mice demonstrate the importance of optimal ex vivo cytokine stimulation for gene transfer to stem cells with retention of their in vivo hematopoietic potential, and also emphasize that overall in vitro transduction frequency does not predict gene transfer to repopulating stem cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044914     DOI: 10.1089/104303400750001435

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

Review 2.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

3.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

4.  Expression, purification and characterization of the extracellular domain of human Flt3 ligand in Escherichia coli.

Authors:  Xingcheng Zhao; Ping Zhang; Qiang Liu; Fei He; Lei Feng; Hua Han
Journal:  Mol Biol Rep       Date:  2009-08-20       Impact factor: 2.316

5.  A novel competitive repopulation strategy to quantitate engraftment of ex vivo manipulated murine marrow cells in submyeloablated hosts.

Authors:  Brandon K Wyss; Justin L Meyers; Anthony L Sinn; Shanbao Cai; Karen E Pollok; W Scott Goebel
Journal:  Exp Hematol       Date:  2008-02-04       Impact factor: 3.084

6.  Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.

Authors:  Marshall W Huston; Adriaan R A Riegman; Rana Yadak; Yvette van Helsdingen; Helen de Boer; Niek P van Til; Gerard Wagemaker
Journal:  Hum Gene Ther       Date:  2014-10       Impact factor: 5.695

7.  Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.

Authors:  Marshall W Huston; Niek P van Til; Trudi P Visser; Shazia Arshad; Martijn H Brugman; Claudia Cattoglio; Ali Nowrouzi; Yuedan Li; Axel Schambach; Manfred Schmidt; Christopher Baum; Christof von Kalle; Fulvio Mavilio; Fang Zhang; Mike P Blundell; Adrian J Thrasher; Monique M A Verstegen; Gerard Wagemaker
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

8.  Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE.

Authors:  Rana Yadak; Raquel Cabrera-Pérez; Javier Torres-Torronteras; Marianna Bugiani; Joost C Haeck; Marshall W Huston; Elly Bogaerts; Steffi Goffart; Edwin H Jacobs; Merel Stok; Lorena Leonardelli; Luca Biasco; Robert M Verdijk; Monique R Bernsen; George Ruijter; Ramon Martí; Gerard Wagemaker; Niek P van Til; Irenaeus F M de Coo
Journal:  Mol Ther Methods Clin Dev       Date:  2018-01-08       Impact factor: 6.698

9.  Angiopoietin-like protein 3 promotes preservation of stemness during ex vivo expansion of murine hematopoietic stem cells.

Authors:  Elnaz Farahbakhshian; Monique M Verstegen; Trudi P Visser; Sima Kheradmandkia; Dirk Geerts; Shazia Arshad; Noveen Riaz; Frank Grosveld; Niek P van Til; Jules P P Meijerink
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

10.  Transplantation, gene therapy and intestinal pathology in MNGIE patients and mice.

Authors:  Rana Yadak; Max V Boot; Niek P van Til; Dominique Cazals-Hatem; Armin Finkenstedt; Elly Bogaerts; Irenaeus F de Coo; Marianna Bugiani
Journal:  BMC Gastroenterol       Date:  2018-10-19       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.